Jung K., Klotzek S., Stephan C., Mannello F., Lein M.Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. Clin Chem2008; 54: 772-774.
2.
Mannello F., Jung K., Tonti GA, Canestrari F.Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. Clin Biochem2008; 41: 1466-1473.
3.
Meisser A., Cohen M., Bischof P.Concentrations of circulating gelatinases (matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Clin Chem2005; 51: 274-276.
4.
Fainardi E., Castellazzi M., Bellini T., Dallocchio F.Matrix metalloproteinases (MMP): Determination of different forms by different techniques may require different preanalytical strategies. Mult Scler2007; 13: 691-692.
5.
Avolio C., Ruggieri M., Giuliani F., et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol2003; 136: 46-53.
6.
Liuzzi GM, Trojano M., Fanelli M., et al. Intrathecal synthesis of matrixmetalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler2002; 8: 222-228.
7.
Waubant E., Goodkin DE, Gee L., et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology1999 ; 53: 1397-1401.
8.
Waubant E., Goodkin D., Bostrom A., et al. IFN beta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology2003 ; 60: 52-57.
